Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

» Details

Guru Trades

Q3 2015

VEU Guru Trades in Q3 2015

First Eagle Investment 73,800 sh (unchged)
» More
Q4 2015

VEU Guru Trades in Q4 2015

First Eagle Investment 9,800 sh (-86.72%)
» More
Q1 2016

VEU Guru Trades in Q1 2016

First Eagle Investment 9,800 sh (unchged)
» More
Q2 2016

VEU Guru Trades in Q2 2016

First Eagle Investment Sold Out
» More

Ratios

vs
industry
vs
history
P/E(ttm) 15.99
VEU's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VEU: 15.99 )
Ranked among companies with meaningful P/E(ttm) only.
VEU' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 16.08
Current: 15.99
0
16.08
PE(NRI) 15.99
VEU's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VEU: 15.99 )
Ranked among companies with meaningful PE(NRI) only.
VEU' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 16.08
Current: 15.99
0
16.08
P/B 1.56
VEU's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VEU: 1.56 )
Ranked among companies with meaningful P/B only.
VEU' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.62
Current: 1.56
0
1.62

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.81
VEU's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VEU: 2.81 )
Ranked among companies with meaningful Dividend Yield only.
VEU' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.9
Current: 2.81
0
2.9
Yield on cost (5-Year) 2.81
VEU's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. VEU: 2.81 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
VEU' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.9
Current: 2.81
0
2.9

More Statistics

Short Percentage of Float0.00%
52-Week Range $38.18 - 46.37
Shares Outstanding (Mil)99,999,999.99
» More Articles for VEU

Headlines

Articles On GuruFocus.com
Abbott Receives FDA Approval for Freestyle Libre Sep 30 2016 
Himax’s Pullback Is an Opportunity Sep 30 2016 
Halliburton Is in Good Shape Sep 30 2016 
Betting on Chevron Makes Sense Sep 30 2016 
Lifeway Looks Good Sep 30 2016 
Warning Signs Identify Value Declining Companies Sep 30 2016 
EnSync Insider Purchases 1,306,737 Shares Sep 30 2016 
Pearson PLC's Stock Yields Over 7% Sep 30 2016 
Dunkin’ Donuts to Release Bottled Beverages Sep 30 2016 
Insider Slashes 65,000 Computer Science Shares Sep 30 2016 

More From Other Websites
Novo Nordisk Is Number One Player in Diabetes Care Market in 2016 Sep 30 2016
Understanding Strong Growth Trends in Insulin and Novo Nordisk’s Profitability Sep 30 2016
Teva’s Research Pipeline and Generic Product Launches in 2016 Sep 30 2016
Why Novo Nordisk Expects Double-Digit Growth in Diabetes Care in 2016 Sep 30 2016
Geographic Diversification Has Helped Novo Nordisk Offset Modest US Sales Sep 29 2016
Strong Brand Positioning Expected to Strengthen Teva’s Position Sep 29 2016
August Steel Production: Asia Rocks While US and Europe Sag Sep 29 2016
Teva’s Generic Business and Its Transformation in Europe Sep 29 2016
Is Shell’s Leverage Still Trending Higher? Sep 29 2016
Teva Pharmaceutical Still Dominates the Generic Market in Europe Sep 28 2016
Teva’s OTC Business Is Playing out to Be a Key Growth Driver Sep 27 2016
Will Political and Economic Risk Mean Volatility in Europe? Sep 26 2016
How Teva’s Analysts Suggest Investors Play Its Stock Sep 26 2016
Chevron’s Refined Products Markets: Is International Exposure High? Sep 22 2016
What Is the Upside Potential for Valeant? Sep 21 2016
Should You Bet on ArcelorMittal amid Falling US Steel Prices? Sep 21 2016
How Will Valeant’s Profitability Pan Out over the Long Term? Sep 20 2016
Why Valeant Offers Volume-Based Discounts for These Drugs Sep 20 2016
Is Interest from Institutional Investors Picking Up for Tesoro? Sep 19 2016
And Then There’s Merck—Another Competitor for Roche in Oncology Sep 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK